Medchemexpress LLC NX-2127 | 2416131-46-7 | C39H45N9O5 | 500 MG

Supplier:  Medchemexpress LLC HY153220500MG

Zelebrudomide (NX-2127) is an orally active PROTAC degrader that targets Bruton's Tyrosine Kinase (Btk). It inhibits the proliferation of BTKC481S mutant TMD8 cells more effectively than Ibrutinib. In vivo, it demonstrates potent degradation of BTK in cynomolgus monkeys and leads to superior tumor growth inhibition in both WT TMD8 and C481S mutant xenograft models in mice.

• Inhibits proliferation of BTKC481S mutant TMD8 cells
• Catalyzes the degradation of Ikaros (IKZF1) and Aiolos (IKZF3)
• Stimulates T cell activation and increases IL-2 production
• Demonstrates potent degradation of BTK in cynomolgus monkeys
• Leads to superior tumor growth inhibition in xenograft models in mice

Catalog No. 50-003-72641